comparemela.com

Latest Breaking News On - Endoxifen versus - Page 1 : comparemela.com

Atossa Therapeutics Presents Data from 40mg Cohort of Phase

Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update

Fully enrolled two Phase 2 studies with data from both expected in the second half of 2024First patient dosed in new Phase 2 breast cancer prevention studyData from ongoing Phase

United-states
Australia
New-york
American
Australian
Jonathan-finn
Tessa-cigler
Eric-van-zanten
Matthew-goetz
Development-expense
Atossa-therapeutics-inc
Weill-cornell-breast-center

Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update

Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New-york
United-states
Australia
American
Australian
Matthew-goetz
Eric-van-zanten
Jonathan-finn
Tessa-cigler
Weill-cornell-breast-center
Exchange-commission
Australian-taxation-office

Atossa Therapeutics Issues Letter to Shareholders

SEATTLE, Jan. 09, 2024 Atossa Therapeutics, Inc. , a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus.

United-states
California
San-francisco
Eric-van-zanten
Matthew-goetz
Weill-cornell
Nasdaq
Exchange-commission
Mayo-clinic-comprehensive-cancer-center
Globenewswire-inc
University-of-california
Breast-cancer-research-foundation

Atossa Therapeutics (ATOS) Approved in Canada to Conduct Phase 2 EVANGELINE Trial

Atossa Therapeutics (ATOS) Approved in Canada to Conduct Phase 2 EVANGELINE Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Canada
United-states
Eric-van-zanten
Atossa-therapeutics-inc
Company-clinical-trial-application
Health-canada
Exchange-commission
Atossa-therapeuticsatossa-therapeutics-inc
Nasdaq
Atossa-therapeutics
Clinical-trial-application
© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.